Free Trial

Cadrenal Therapeutics (CVKD) Competitors

Cadrenal Therapeutics logo
$12.92 -0.08 (-0.62%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$12.98 +0.06 (+0.46%)
As of 07/11/2025 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVKD vs. FBRX, CLLS, CLYM, CABA, MCRB, TCRX, VNRX, SRZN, EPIX, and PLRX

Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry.

Cadrenal Therapeutics vs. Its Competitors

Forte Biosciences (NASDAQ:FBRX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Forte Biosciences had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 3 mentions for Forte Biosciences and 1 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 1.87 beat Forte Biosciences' score of 1.29 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Forte Biosciences Positive
Cadrenal Therapeutics Very Positive

Forte Biosciences currently has a consensus target price of $61.00, suggesting a potential upside of 478.20%. Cadrenal Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 147.68%. Given Forte Biosciences' higher possible upside, equities analysts plainly believe Forte Biosciences is more favorable than Cadrenal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forte Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cadrenal Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Forte Biosciences' return on equity of -149.15% beat Cadrenal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Forte BiosciencesN/A -149.15% -114.25%
Cadrenal Therapeutics N/A -244.94%-181.94%

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte BiosciencesN/AN/A-$35.48M-$16.29-0.65
Cadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.40

Forte Biosciences has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Summary

Forte Biosciences beats Cadrenal Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVKD vs. The Competition

MetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$25.57M$2.99B$5.60B$9.11B
Dividend YieldN/A2.39%5.24%4.02%
P/E Ratio-1.4020.5827.9620.25
Price / SalesN/A292.00430.8999.65
Price / CashN/A42.8637.4658.16
Price / Book3.107.638.045.49
Net Income-$10.65M-$55.05M$3.18B$250.27M
7 Day Performance5.13%8.39%3.63%4.75%
1 Month Performance-13.81%5.35%4.04%7.64%
1 Year PerformanceN/A1.95%29.55%16.34%

Cadrenal Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVKD
Cadrenal Therapeutics
2.9547 of 5 stars
$12.92
-0.6%
$32.00
+147.7%
N/A$25.57MN/A-1.404Positive News
FBRX
Forte Biosciences
3.5262 of 5 stars
$12.93
+5.6%
$61.00
+371.8%
+40,918.7%$80.65MN/A-0.795Positive News
Options Volume
Gap Down
CLLS
Cellectis
3.3631 of 5 stars
$1.53
+5.2%
$4.00
+162.3%
-20.9%$80.60M$49.22M-1.77290
CLYM
Climb Bio
3.508 of 5 stars
$1.24
+5.1%
$9.00
+625.8%
N/A$79.74MN/A-0.529News Coverage
Positive News
CABA
Cabaletta Bio
2.5851 of 5 stars
$1.52
-3.2%
$14.43
+849.2%
-78.8%$79.67MN/A-0.6050News Coverage
Positive News
Gap Up
MCRB
Seres Therapeutics
3.3243 of 5 stars
$11.11
+22.1%
$73.67
+563.1%
-35.7%$79.46M$126.32M-2.42330Positive News
Gap Down
High Trading Volume
TCRX
TScan Therapeutics
3.6093 of 5 stars
$1.45
+3.6%
$7.80
+437.9%
-73.5%$79.23M$2.82M-1.33100News Coverage
Positive News
Analyst Upgrade
VNRX
VolitionRx
2.1165 of 5 stars
$0.76
-9.3%
$3.50
+360.5%
+3.5%$78.30M$1.31M-2.1180News Coverage
Analyst Forecast
SRZN
Surrozen
2.7693 of 5 stars
$8.94
-0.9%
$38.50
+330.6%
-12.4%$77.24M$10.65M-0.3680Positive News
Gap Down
High Trading Volume
EPIX
ESSA Pharma
1.9304 of 5 stars
$1.70
-1.7%
$2.00
+17.6%
-67.4%$76.79MN/A-2.7050Positive News
PLRX
Pliant Therapeutics
4.4941 of 5 stars
$1.16
-7.2%
$13.31
+1,047.6%
-88.7%$76.73M$1.58M-0.3290News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:CVKD) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners